Oct 10, 2015 8:00am EDT Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
Oct 05, 2015 7:00am EDT Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 – An Orally Delivered, Encochleated Formulation of Amphotericin B –
Sep 19, 2015 2:00pm EDT Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
Sep 18, 2015 3:00pm EDT Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
Sep 17, 2015 7:00am EDT Matinas BioPharma Appoints International Expert and Thought Leader on Invasive Fungal Infections Peter G. Pappas, M.D., FACP, to Scientific Advisory Board
Sep 02, 2015 7:05am EDT Matinas BioPharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015
Sep 01, 2015 7:00am EDT Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
Aug 18, 2015 7:00am EDT Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA
Jul 27, 2015 7:05am EDT Matinas BioPharma Announces Abstract on Pharmacokinetics and Efficacy of Encochleated Atovaquone in Murine Model of Pneumocystis Accepted for Oral Presentation at IDWeek 2015
Jul 23, 2015 7:05am EDT Matinas BioPharma Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board
